- Financing led by LongRiver Investments with participation by
new and existing global investment funds
- Rona will use proceeds to progress leading metabolic siRNA
pipeline programs into global development and expand extra-hepatic
delivery platform in CNS and beyond
SHANGHAI, July 19,
2024 /CNW/ -- Rona Therapeutics, a clinical stage
pioneering platform company in nucleic acid drug research and
development, today announced the completion of $35 Million Series A+ financing. This round was
led by LongRiver Investments, with participation from investors
including Zhaode Investment, BioTrack Capital, Zhongqi Capital and
Lilly Asia Ventures.
LongRiver Investments will join the board of Rona in connection
with the Series A+ financing, commented, "Rona Therapeutics has
successfully brought two best-in-class siRNA metabolic programs
into global development and demonstrated differentiated clinical
data and platform value. We are impressed by the progress Rona has
made in developing innovative siRNA pipeline and expanding into
extrahepatic delivery in CNS and beyond. We look forward to
partnering with Rona team to unlock potential of RNA medicine as
transformative therapies to patients globally."
Ms. Stella SHI, CEO and Founder of Rona Therapeutics, commented,
"We are thrilled to welcome LongRiver Investments and our other new
investors as we progress more best-in-class and first-in-class
siRNA programs into global development and catalyzing potential
business development opportunities. Rona Therapeutics remains
committed to pushing boundaries of RNA medicine in metabolic,
obesity, renal and neuro degenerative diseases with Rona's
proprietary RNA platform."
Rona is advancing a pipeline of best and first-in-class siRNA
programs generated from next generation siRNA platform. The
company's first program RN0191, a best-in-class PCSK9 siRNA
program, has completed Australia
and China Ph1 clinical studies and
ready for Ph2 clinical development for hypercholesterolemia. RN0361
is the company's second program to enter clinic in 2024Q2 for
hypertriglyceridemia. The company is also advancing innovative
pipeline at IND enabling stage for kidney disease, obesity and
cardiometabolic diseases.
About Rona Therapeutics
Rona Therapeutics is a global
leader in nucleic acid innovative drug platform company,
specializing in the treatment of metabolic diseases and CNS
degenerative diseases. Rona Therapeutics is always committed to
developing the best and first-in-class siRNA drugs, and has unique
differentiation and innovation in its liver-targeted
metabolism-related pipeline products in cardiovascular diseases,
MASH, obesity, and kidney diseases. In addition, Rona Therapeutics
is focusing on the potential of extra-hepatic nucleic acid delivery
in CNS degenerative diseases and has successfully established a
proprietary extra-hepatic delivery platform to treat a range of
complex diseases, such as ALS, Alzheimer's disease, etc. which are
difficult to treat with traditional drug therapies.
About LongRiver Investments
LongRiver Investments is a
forward-thinking venture capital firm dedicated to empowering
entrepreneurs and driving technological and industrial
advancements. With a robust investment strategy and a commitment to
excellence, LongRiver Investments aims to deliver superior returns
to its investors while making a positive impact on the global
market.
For Further information,
Please visit: www.ronatherapeutics.com or
contact: BD@ronatherapeutics.com
View original
content:https://www.prnewswire.com/news-releases/rona-therapeutics-raises-35-million-series-a-financing-to-advance-innovative-metabolic-sirna-pipeline-in-clinic-and-next-generation-rna-platforms-302200539.html
SOURCE Rona Therapeutics